Myelodysplastic Syndrome
From the Journals
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Conference Coverage
CMML: GM-CSF inhibitor lenzilumab shows early promise
The PREACH-M trial has yielded encouraging preliminary results in treating CMML, a rare, “insidious” leukemia that can transform into AML.
Conference Coverage
'Paradigm shift’: Luspatercept for MDS
In a first head-to-head comparison study, luspatercept for MDS significantly outperformed epoetin alfa in reducing transfusion dependence.
Conference Coverage
ASCO honors Hagop Kantarjian, MD, for leukemia research
Noted Lebanese-American oncologist who leads the leukemia department at MD Anderson Cancer Center is to receive a top award at ASCO 2023.
From the Journals
Red-cell donor’s sex does not affect transfusion survival
New study showed that the sex of a red blood cell donor has no bearing on the survival of the transfusion recipient.
Feature
New hope for MDS, with AML treatments
Slow progress in treating myelodysplastic syndrome is coming mostly with therapies first developed for acute myeloid leukemia.
From the Journals
VEXAS syndrome: More common, variable, and severe than expected
A large U.S. analysis found that this newly discovered genetic disease has a estimated prevalence of 1 in 4,269 in men older than 50.
Bloodlines
Bias and other barriers to HSCT access
A view from the world of cellular therapy and hematopoietic stem cell transplantation.